MetaCap

Propanc Biopharma (PPCB) vs XORTX Therapeutics (XRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XORTX Therapeutics is the larger company by market cap ($1.9 million vs $1.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PPCB+256.93%XRTX-51.92%
+409%+168%-74%
Oct 7, 20261 yearNov 20, 2026
PPCB+266.48%XRTX-40.50%
+317%+129%-59%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PPCB versus XRTX key metrics
MetricPPCBXRTX
Share price$1.78$0.839
Market cap$1.87M$1.88M
1-day change+3.19%-5.73%
Forward P/E—1.05
EPS (TTM)$-95.92$-2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-18.86M—
52-week high$315.00$3.60
52-week low$1.61$0.81
Distance from 52-week high-99.43%-76.69%
Average volume188.66K776.48K
Shares outstanding1.05M2.25M
Employees2—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Propanc Biopharma

PPCB stock →

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About XORTX Therapeutics

XRTX stock →

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.

Health Care · Biotechnology: Pharmaceutical Preparations

PPCB vs XRTX FAQ

Which is bigger, Propanc Biopharma or XORTX Therapeutics?

XORTX Therapeutics (XRTX) is larger, with a market capitalization of $1.88M compared with $1.87M for Propanc Biopharma (PPCB).

Are Propanc Biopharma and XORTX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons